Treatment library
Loading treatment roster
Preparing current medications, procedures, devices, and historical context.
Treatment library
Preparing current medications, procedures, devices, and historical context.
Eli Lilly’s tirzepatide brand for type 2 diabetes. It is frequently compared with Zepbound because both use tirzepatide but have different labels and access pathways.
FDA-approved for type 2 diabetes, not for chronic weight management. The obesity label for tirzepatide is Zepbound.
Dual GIP and GLP-1 receptor agonist
Often tied to diabetes diagnosis, formulary rules, and prior authorization rather than obesity-benefit design.
Dual GIP and GLP-1 receptor agonist
Eli Lilly’s tirzepatide brand for type 2 diabetes. It is frequently compared with Zepbound because both use tirzepatide but have different labels and access pathways.
medication
current
2022
Mounjaro
tirzepatide
Eli Lilly and Company
No.
tirzepatide
High branded cash-pay medication. Diabetes labeling may change some insurance pathways, but out-of-pocket exposure remains substantial without coverage.
Often tied to diabetes diagnosis, formulary rules, and prior authorization rather than obesity-benefit design.
Relevant for understanding tirzepatide access, molecule overlap, and diabetes-versus-obesity brand confusion.
Mounjaro is approved for type 2 diabetes, not obesity. There is no BMI threshold in the label. Off-label weight-loss prescribing exists but is not the approved indication.
The list price is roughly $1,060 per month, the same as Zepbound. Diabetes coverage may be more accessible than obesity coverage in many plans, which can make Mounjaro easier to obtain for patients with a type 2 diabetes diagnosis. Manufacturer savings programs are available.
The same molecule confusion that affects Ozempic and Wegovy also applies here. Patients on Mounjaro for diabetes may not know Zepbound exists as the dedicated obesity label, or they may have started Mounjaro and been surprised by the weight-loss effects. The dosing schedule, pen format, and dose steps are identical to Zepbound.
Mounjaro matters in obesity coverage because many readers encounter it before they understand the separate Zepbound weight-management label.
The SURPASS trials studied Mounjaro for type 2 diabetes, not obesity. Key results: HbA1c reduction of up to 2.4%. Weight loss of roughly 15 to 25 pounds was observed as a secondary outcome depending on dose, which is more than most diabetes medications produce. These are not pivotal obesity trial results; the obesity label for tirzepatide is Zepbound.
Class warnings mirror Zepbound closely because the active ingredient is the same tirzepatide molecule.
nausea, diarrhea, decreased appetite, vomiting, constipation
The gastrointestinal profile mirrors Zepbound because the active molecule is the same tirzepatide. Nausea, diarrhea, and decreased appetite are the most common side effects. The GI burden is concentrated during dose escalation and generally manageable at maintenance.
Dual GIP and GLP-1 receptor agonist
Once-weekly subcutaneous injection with escalation from 2.5 mg up to 15 mg for labeled diabetes use.
Single-dose pen or vial format depending on supply pathway.
These are the official or reference sources used to anchor this treatment profile.
Treatment availability, dosing, cash pricing, and insurance coverage change often. Verify current details with your clinician, pharmacist, surgeon, device program, and insurer before starting, switching, or paying for treatment.